Helen M. Thackray, Chief R&D Officer at BIOCRYST PHARMACEUTICALS INC (BCRX), bought 30,000 shares at $5.86 ($176K) on 2024-05-14, disclosed to the SEC on 2024-05-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| BCRX | SELL | 2022-04-04 | $123K | — | Filing → |
| GLYC | SELL | 2017-12-12 | $30K | — | Filing → |
| GLYC | SELL | 2017-09-18 | $26K | — | Filing → |